Glaxo Bid Undervalues Human Genome Sciences, Sunday Times Says
Mark Evans from Taube Hodson Stonex Partners LLP, a fund manager that owns 5.6 percent of the U.S. drugs maker, termed the bid “unacceptable,” the London-based newspaper said.
Human Genome rejected Glaxo’s $13-a-share cash offer on April 19.
To contact the reporter on this story: Lucy Meakin in London at email@example.com
To contact the editor responsible for this story: Daniel Tilles at firstname.lastname@example.org
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.